Chemodex

Trazodone hydrochloride

As low as CHF 45.00
In stock
Only %1 left
CDX-T0476-G0011 gCHF 45.00
CDX-T0476-G0055 gCHF 103.00
NEW
 
More Information
Product Details
Synonyms 2-[3-[4-(3-Chlorophenyl)-1-piperazinyl]propyl]-1,2,4-triazolo[4,3-a]pyridin-3(2H)-one hydrochloride; AF 1161; Desyrel; Molipaxin; KB 831; Pragmazone; Thombran; Trazolan; Tombran; Trittico; Bimaran; Mesyrel
Product Type Chemical
Properties
Formula C19H22ClN5O . HCl
MW 408.32
CAS 25332-39-2
RTECS XZ5660000
Source/Host Chemicals Synthetic
Purity Chemicals ≥99% (HPLC)
Appearance White to off-white powder.
Solubility Soluble in DMSO (10mg/ml), methanol (10mg/ml) or water (1mg/ml).
Identity Determined by 1H-NMR.
Declaration Manufactured by Chemodex.
Other Product Data

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.

InChi Key OHHDIOKRWWOXMT-UHFFFAOYSA-N
Smiles ClC1=CC=CC(N(CC2)CCN2CCCN3N=C(C=CC=C4)N4C3=O)=C1.Cl
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Protect from light and moisture.
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Documents
Product Specification Sheet
Datasheet Download PDF
Description
Trazodone hydrochloride belongs to the class of serotonin receptor antagonists and reuptake inhibitors (SARIs). Trazodone hydrochloride has anti-depressant and neuroprotectant activity. Trazodone hydrochloride exerts antagonistic properties against α1- and α2-adrenergic receptors and histamine H1 receptors, with minimal anticholinergic effects. Shown to enhance neuronal differentiation of mouse and human neural progenitor cells. Also inhibits PERK/eIF2α-P-mediated reduction in protein synthesis and restores memory deficits in a mouse dementia model. Its broad pharmacological activity makes it a valuable tool in both neuroscience research and therapeutic development. Can be used as a reference compound.
Product References
(1) A. Georgotas, et al.; Pharmacotherapy 2, 255 (1982) | (2) S.G. Bryant & L. Ereshefsky; Clin. Pharm. 1, 406 (1982) | (3) A. Fagiolini, et al.; Review CNS Drugs 26, 1033 (2012) | (4) M. Halliday, et al.; Brain 140, 1768 (2017) | (5) V. Bortolotto, et al.; ACS Chem. Neurosci. 8, 2027 (2017)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.